文献速递乳腺癌妇科肿瘤

FANCM基因功能缺失突变与早发性家族性乳腺癌的关联

Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast Cancer.
PubMed 文献 · JAMA Oncol · 2017-01-01

该病例对照研究对2047例家族性乳腺癌先证者、628例卵巢癌患者和2187例地理匹配对照进行FANCM基因功能缺失突变筛查。FANCM杂合功能缺失突变与家族性乳腺癌风险显著相关,总体OR为2.05(95%CI 0.94-4.54;P=.049),在51岁前发病的家族性乳腺癌患者中OR为2.44(95%CI 1.08-5.59;P=.02),三阴性乳腺癌表型患者OR为3.75(95%CI 1.00-12.85;P=.02)。未选择的卵巢癌病例中未检测到显著关联(OR 1.74;95%CI 0.57-5.08;P=.27)。

要点

  • FANCM杂合功能缺失突变与家族性乳腺癌风险相关,总体OR为2.05(95%CI 0.94-4.54;P=.049)。
  • 51岁前发病的家族性乳腺癌患者OR为2.44(95%CI 1.08-5.59;P=.02)。
  • 三阴性乳腺癌表型患者OR为3.75(95%CI 1.00-12.85;P=.02),未选择的卵巢癌病例无显著关联(OR 1.74;95%CI 0.57-5.08;P=.27)。

核心结论

  • 基于杂合功能缺失突变与早发性或三阴性乳腺癌的显著关联,FANCM应被纳入诊断性基因面板检测以进行个体风险评估。
  • 需要更大规模的研究来确定乳腺癌的年龄依赖性疾病风险,并评估FANCM突变在卵巢癌发病机制中的潜在作用。

研究设计与样本

  • 病例对照研究,共纳入2047例特征明确的家族性乳腺癌先证者、628例卵巢癌病例和2187例地理匹配对照,所有患者此前检测为BRCA1和BRCA2致病突变阴性。
  • 通过下一代测序筛查FANCM基因功能缺失突变,数据收集时间为2013年6月1日至2016年4月30日,数据分析时间为2016年5月1日至2016年7月1日。
  • 采用单变量逻辑回归比较乳腺癌和/或卵巢癌患者与地理匹配对照的FANCM功能缺失突变频率,阳性关联按发病年龄和癌症家族史分层。

主要发现

  • FANCM基因杂合功能缺失突变与家族性乳腺癌风险显著相关,总体OR为2.05(95%CI 0.94-4.54;P=.049),先证者中突变频率为1.03%。
  • 在51岁前发病的家族性乳腺癌患者中,观察到OR升高为2.44(95%CI 1.08-5.59;P=.02)。
  • 三阴性乳腺癌肿瘤表型患者中关联更为明显(OR 3.75;95%CI 1.00-12.85;P=.02)。
  • 未选择的卵巢癌病例中未检测到显著关联(OR 1.74;95%CI 0.57-5.08;P=.27)。

临床怎么用

  • 作者认为,基于杂合功能缺失突变与早发性或三阴性乳腺癌的显著关联,FANCM应被纳入诊断性基因面板检测以进行个体风险评估。
  • 作者指出,需要更大规模的研究来确定乳腺癌的年龄依赖性疾病风险,并评估FANCM突变在卵巢癌发病机制中的潜在作用。

局限性

  • 需要更大规模的研究来确定乳腺癌的年龄依赖性疾病风险,并评估FANCM突变在卵巢癌发病机制中的潜在作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Germline mutations in established moderately or highly penetrant risk genes for breast cancer (BC) and/or ovarian cancer (OC), including BRCA1 and BRCA2, explain fewer than half of all familial BC and/or OC cases. Based on the genotyping of 2 loss-of-function (LoF) variants c.5101C>T (p.GIn1701Ter [rs147021911]) and c.5791C>T (p.Arg1931Ter [rs144567652]), the FANCM gene has been suggested as a novel BC predisposition gene, while the analysis of the entire coding region of the FANCM gene in familial index cases and geographically matched controls is pending. OBJECTIVES: To assess the mutational spectrum within the FANCM gene, and to determine a potential association of LoF germline mutations within the FANCM gene with BC and/or OC risk. DESIGN, SETTING, AND PARTICIPANTS: For the purpose of identification and characterization of novel BC and/or OC predisposition genes, a total of 2047 well-characterized familial BC index cases, 628 OC cases, and 2187 geographically matched controls were screened for LoF mutations within the FANCM gene by next-generation sequencing. All patients previously tested negative for pathogenic BRCA1 and BRCA2 mutations. All data collection occurred between June 1, 2013, and April 30, 2016. Data analysis was performed from May 1, 2016, to July 1, 2016. MAIN OUTCOMES AND MEASURES: FANCM LoF mutation frequencies in patients with BC and/or OC were compared with the FANCM LoF mutation frequencies in geographically matched controls by univariate logistic regression. Positive associations were stratified by age at onset and cancer family history. RESULTS: In this case-control study, 2047 well-characterized familial female BC index cases, 628 OC cases, and 2187 geographically matched controls were screened for truncating FANCM alterations. Heterozygous LoF mutations within the FANCM gene were significantly associated with familial BC risk, with an overall odds ratio (OR) of 2.05 (95% CI, 0.94-4.54; P = .049) and a mutation frequency of 1.03% in index cases. In familial patients whose BC onset was before age 51 years, an elevated OR of 2.44 (95% CI, 1.08-5.59; P = .02) was observed. A more pronounced association was identified for patients with a triple-negative BC tumor phenotype (OR, 3.75; 95% CI, 1.00-12.85; P = .02). No significant association was detected for unselected OC cases (OR, 1.74; 95% CI, 0.57-5.08; P = .27). CONCLUSIONS AND RELEVANCE: Based on the significant associations of heterozygous LoF mutations with early-onset or triple-negative BC, FANCM should be included in diagnostic gene panel testing for individual risk assessment. Larger studies are required to determine age-dependent disease risks for BC and to assess a potential role of FANCM mutations in OC pathogenesis.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Neidhardt G, Hauke J, Ramser J, et al. Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast Cancer. JAMA Oncol. 2017. PMID: 28033443. doi:10.1001/jamaoncol.2016.5592

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。